We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Legal & General Pharma Breakthrough UCITS ETF (BIGT)

Sell:778.90p Buy:781.80p 0 Change: No change
Market closed Prices as at close on 25 June 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:778.90p
Buy:781.80p
Change: No change
Market closed Prices as at close on 25 June 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:778.90p
Buy:781.80p
Change: No change
Market closed Prices as at close on 25 June 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
Open:
780.30p
Trade high:
n/a
Year high:
873.60p
Market Listing:
London
Previous close:
780.30p
Trade low:
n/a
Year low:
721.90p
Size:
849.33M
Previous:
19.25p (2.53%)
Previous:
19.25p
Volume:
n/a
Dividend yield:
n/a
Currency:
GBX
Data delayed by at least 15 minutes.

ETP Basics

Issuer: GO UCITS ETF Solutions Plc
Structure: ETF
Replication method: Stocks - Full Replication
Securities lending: No
Number of holdings: 32
Size: 849.3M
Launch date: n/a
Launch price: n/a
UCITS: Yes
Reporting status: Yes
Domicile: n/a
Complex product: Non-complex
ISIN: IE00BF0H7608

Annual & interim reports

Ready to invest?

Invest now

Want to invest?

To buy shares in , you'll need to have an account.

Explore the options

Important Documents

There are no documents available for this stock.

OBJECTIVE

Index: [No Data]
Aim: [No Data]
Read full aim for Legal & General
Leverage: 100%
Currency hedging: n/a

COSTS

Ongoing Charge (OCF/TER): 0.49%
Management fee: 0.75%
Indicative spread: 0.37%

In certain cases, where no TER or OCF is shown, additional costs may apply. Please ensure you have read the Key Investor Information Document, Factsheet, Prospectus and any other relevant documentation prior to investing.

Performance

1 week 1W 3.49% 1 year 1Y 9.38%
1 month 1M 3.96% 2 years 2Y 13.23%
3 months 3M 1.3% 3 years 3Y 18.24%
6 months 6M 2.54% 5 years 5Y 2.33%

Performance figures are based on the previous close price. Past performance is not an indication of future performance.

Security Weight
CHUGAI PHARMACEUTICAL CO 17.38%
TAKEDA PHARMACEUTICAL CO 15.64%
KYOWA HAKKO KIRIN CO. 15.26%
EISAI CO. 15.00%
JCR PHARMACEUTICAL CO 14.81%
NIPPON SHINYAKU CO 14.55%
SWEDISH ORPHAN BIOVITRUM AB (PUBL) 1.45%
INNOVENT BIOLOGICS INC 1.27%
SINO BIOPHAMACEUTICAL 0.98%
INNOCARE PHARMA LTD 0.88%
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Data provided by Broadridge. Some of the data on this page and other related pages is provided to you for your information and is received from the Fund Management Company administering this fund. Hargreaves Lansdown accepts no liability for the reliability or accuracy of the data provided by third parties. Securities lending data correct as at date not available. Charge data correct as at date not available. Holdings correct as at 31 October 2023.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.